Clinical trials: Age Related Maculopathy
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
Age-related Macular Degeneration, Diabetic Macular Edema
Observational Study of Vision Improvement in Patients With Retinal Disorders
The purpose of this study is to assess the vision improvement achieved by patients with retinal disorders who received corneal treatments by a low vision aid device.
- Trial name
- NCT04693702
- Testing
- Corneal treatment by a low vision aid device
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
A Study of EXG102-031 in Patients With wAMD (Everest)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT05903794
- Testing
- EXG102-031
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Dry Age-related Macular Degeneration
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related macular degeneration (AMD).
- Trial name
- NCT01379560
- Testing
- unoprostone isopropyl
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Sucampo Pharma Americas, LLC
Geographic Atrophy
A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.
- Trial name
- NCT01603043
- Testing
- Al-78898A
- Volunteers
- 10 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT04690556
- Testing
- LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 600 people
- Sponsor
- Lupin Ltd.
Macular Degeneration
A Single-Center Pilot Study to Assess Macular Function
This study seeks to evaluate a novel endpoint for future dry AMD clinical trials.
- Trial name
- NCT01204541
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Macular Degeneration
Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD
This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of free and vascular endothelial growth factor (VEGF)-bound abicipar following single and multiple intravitreal injections of abicipar pegol…
- Trial name
- NCT02859766
- Testing
- Abicipar pegol
- Where
- 18 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergan
Age Related Macular Degeneration
Visual Function Tests in Age-related Macular Degeneration
The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
- Trial name
- NCT03275753
- Testing
- Visual Function Tests
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Macular Degeneration, Choroidal Neovascularization
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina.
- Trial name
- NCT00509548
- Testing
- TG100801
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- TargeGen
Exudative Age-Related Macular Degeneration
ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative…
- Trial name
- NCT01304693
- Testing
- ESBA1008 solution, Ranibizumab 0.5 mg
- Volunteers
- 376 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
This Phase IIIb, single-arm, open-label multicenter clinical in-use study in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is designed to assess the ability of the intended…
- Trial name
- NCT05569148
- Testing
- Faricimab PFS Configuration
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.
- Trial name
- DAVIO2 (NCT05381948)
- Testing
- EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph
- Where
- 67 sites in United States
- Volunteers
- 161 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Macular Degeneration
Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD.
- Trial name
- NCT00078221
- Testing
- Rheopheresis blood filtration
- Where
- 8 sites in United States, Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- OccuLogix
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
- Trial name
- SIENNA (NCT06541704)
- Testing
- Pozelimab, Cemdisiran
- Where
- 233 sites in United States, Australia and 9 more
- Volunteers
- 975 people
- Sponsor
- Regeneron Pharmaceuticals
Macular Degeneration
A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration
The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- CABERNET (NCT00454389)
- Testing
- Epi-Rad90™ Ophthalmic System, ranibizumab
- Where
- 32 sites in United States, Austria and 7 more
- Volunteers
- 494 people
- Sponsor
- NeoVista
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG
Macular Degeneration
Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)
This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration…
- Trial name
- NCT00414206
- Testing
- Mecamylamine
- Where
- 42 sites in Brazil, Czechia and 4 more
- Volunteers
- 343 people
- Sponsor
- CoMentis
Age - Related Macular Degeneration, Diabetic Retinopathy
A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
The CLEAR study is testing the level of agreement between visual acuity and Amsler grid testing using a mobile vision testing application, Checkup Study, and standard in office methods.
- Conditions
- Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
- Trial name
- CLEAR (NCT02871817)
- Testing
- Paxos Checkup Study Mobile Medical Application
- Where
- 12 sites in United States
- Volunteers
- 143 people
- Sponsor
- Digisight Technologies, Inc.
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer